MedKoo Cat#: 525590 | Name: RI(dl)-2 TFA
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RI(dl)-2 is a selective inhibitor of Rad51-mediated D-loop formation.

Chemical Structure

RI(dl)-2 TFA
RI(dl)-2 TFA
CAS#2140803-88-7 (TFA)

Theoretical Analysis

MedKoo Cat#: 525590

Name: RI(dl)-2 TFA

CAS#: 2140803-88-7 (TFA)

Chemical Formula: C21H18F3N3O2

Exact Mass: 0.0000

Molecular Weight: 401.39

Elemental Analysis: C, 62.84; H, 4.52; F, 14.20; N, 10.47; O, 7.97

Price and Availability

Size Price Availability Quantity
5mg USD 450.00 2 Weeks
10mg USD 750.00 2 Weeks
25mg USD 1,650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1902146-75-1 (free base) 2140803-88-7 (TFA)
Synonym
RI(dl)-2; RI(dl)-2 TFA salt. RI(dl)-2 trifluoroacetic acid
IUPAC/Chemical Name
N-Ethyl-4-(pyrrolo[1,2-a]quinoxalin-4-yl)aniline trifluoroacetic acid
InChi Key
NIJZNZBFNNPMPH-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H17N3.C2HF3O2/c1-2-20-15-11-9-14(10-12-15)19-18-8-5-13-22(18)17-7-4-3-6-16(17)21-19;3-2(4,5)1(6)7/h3-13,20H,2H2,1H3;(H,6,7)
SMILES Code
CCNC1=CC=C(C2=NC3=C(N4C2=CC=C4)C=CC=C3)C=C1.O=C(O)C(F)(F)F
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Certificate of Analysis
Safety Data Sheet (SDS)
Biological target:
RI(dl)-2 is a cell-permeable pyrroloquinoxaline derivative that selectively inhibits Rad51-mediated D-loop formation (IC50 = 11.1 μM) without affecting its ssDNA-binding activity (IC50 >100 μM). RI(dl)-2 inhibits DSBs-induced cellular homologous recombination (HR) activity (IC50 = 3.0 μM by HEK293-based DR-GFP reporter assay) by stabilizing nucleoprotein filaments in a nonfunctional state without affecting DNA damage-induced RAD51 nuclear loci formation or stimulating single-strand annealing (SSA) activity.
In vitro activity:
This study developed a sensitive assay to measure dsDNA intercalation and identified two analogues of RI(dl)-2 that promote complete homologous recombination inhibition in cells while exerting minimal intercalation activity. Reference: ChemMedChem. 2019 May 17;14(10):1031-1040. https://pubmed.ncbi.nlm.nih.gov/30957434/
In vivo activity:
To be determined

Preparing Stock Solutions

The following data is based on the product molecular weight 401.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Budke B, Tueckmantel W, Miles K, Kozikowski AP, Connell PP. Optimization of Drug Candidates That Inhibit the D-Loop Activity of RAD51. ChemMedChem. 2019 May 17;14(10):1031-1040. doi: 10.1002/cmdc.201900075. Epub 2019 Apr 17. PMID: 30957434; PMCID: PMC6525040. 2. Lv W, Budke B, Pawlowski M, Connell PP, Kozikowski AP. Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51. J Med Chem. 2016 May 26;59(10):4511-25. doi: 10.1021/acs.jmedchem.5b01762. Epub 2016 Apr 21. PMID: 27049177; PMCID: PMC5473336.
In vitro protocol:
1. Budke B, Tueckmantel W, Miles K, Kozikowski AP, Connell PP. Optimization of Drug Candidates That Inhibit the D-Loop Activity of RAD51. ChemMedChem. 2019 May 17;14(10):1031-1040. doi: 10.1002/cmdc.201900075. Epub 2019 Apr 17. PMID: 30957434; PMCID: PMC6525040. 2. Lv W, Budke B, Pawlowski M, Connell PP, Kozikowski AP. Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51. J Med Chem. 2016 May 26;59(10):4511-25. doi: 10.1021/acs.jmedchem.5b01762. Epub 2016 Apr 21. PMID: 27049177; PMCID: PMC5473336.
In vivo protocol:
To be determined
1. Budke B, Tueckmantel W, Miles K, Kozikowski AP, Connell PP. Optimization of Drug Candidates That Inhibit the D-Loop Activity of RAD51. ChemMedChem. 2019 May 17;14(10):1031-1040. doi: 10.1002/cmdc.201900075. Epub 2019 Apr 17. PMID: 30957434; PMCID: PMC6525040. 2. Lv W, Budke B, Pawlowski M, Connell PP, Kozikowski AP. Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51. J Med Chem. 2016 May 26;59(10):4511-25. doi: 10.1021/acs.jmedchem.5b01762. Epub 2016 Apr 21. PMID: 27049177; PMCID: PMC5473336.